IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials

Clinical Immunology Communications Pub Date : 2023-07-20 DOI:10.1016/j.clicom.2023.07.001

Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan

{"title":"IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials","authors":"Ahmed Safi Vahidy , Faizan Niaz , Samiuddin Tariq , Irtebaat Fatima , Yusra Afzal , Abdulqadir J. Nashwan","doi":"10.1016/j.clicom.2023.07.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><p>To review the available evidence on the efficacy and safety profiles of four Interleukin-23 inhibitors in patients with Psoriatic Arthritis.</p></div><div><h3>Methods</h3><p>Several databases were searched till July 2022. A total of 11 RCTs with at least one treatment arm were included. All articles were in English. The primary outcomes were ACR20, HAQ-DI, PASI90, and TEAEs experienced by the patients.</p></div><div><h3>Results</h3><p>Compared to other groups, Guselkumab had the strongest association with ACR20 response (RR: 2.14; 95% CI: 1.84-2.49, <em>p < 0.00001</em>), while a mean change in HAQ-DI (MD: -0.24; 95% CI: -0.41- -0.13, <em>p = 0.0001</em>) and PASI90 (RR: 9.81; 95% CI: 3.18-30.22; <em>p <0.01</em>) were most strongly associated with Ustekinumab. TEAEs were significantly present in the Guselkumab group (RR: 1.26; 95% CI: 1.00 - 1.59; <em>p = 0.05</em>).</p></div><div><h3>Conclusion</h3><p>Although our analysis suggests that IL-23 inhibitors are efficacious at treating psoriatic arthritis, further studies are required for long-term outcomes.</p></div>","PeriodicalId":100269,"journal":{"name":"Clinical Immunology Communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Immunology Communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772613423000197","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

To review the available evidence on the efficacy and safety profiles of four Interleukin-23 inhibitors in patients with Psoriatic Arthritis.

Methods

Several databases were searched till July 2022. A total of 11 RCTs with at least one treatment arm were included. All articles were in English. The primary outcomes were ACR20, HAQ-DI, PASI90, and TEAEs experienced by the patients.

Results

Compared to other groups, Guselkumab had the strongest association with ACR20 response (RR: 2.14; 95% CI: 1.84-2.49, p < 0.00001), while a mean change in HAQ-DI (MD: -0.24; 95% CI: -0.41- -0.13, p = 0.0001) and PASI90 (RR: 9.81; 95% CI: 3.18-30.22; p <0.01) were most strongly associated with Ustekinumab. TEAEs were significantly present in the Guselkumab group (RR: 1.26; 95% CI: 1.00 - 1.59; p = 0.05).

Conclusion

Although our analysis suggests that IL-23 inhibitors are efficacious at treating psoriatic arthritis, further studies are required for long-term outcomes.

查看原文本刊更多论文

IL-23抑制剂治疗银屑病关节炎:随机对照试验的系统回顾和荟萃分析

目的综述四种白细胞介素-23抑制剂对银屑病患者的疗效和安全性的现有证据。方法检索截至2022年7月的多个数据库。共纳入11项随机对照试验，其中至少有一个治疗组。所有文章都是英文的。主要结果是患者经历的ACR20、HAQ-DI、PASI90和TEAE。结果与其他组相比，Guselkumab与ACR20反应的相关性最强（RR:2.14；95%CI:1.84-2.49，p<；0.00001），而HAQ-DI（MD:0.24；95%CI:0.41--0.13，p=0.0001）和PASI90（RR:9.81；95%CI:3.18-3.22；p<；0.01）的平均变化与Ustekinumab的相关性最强。在Guselkumab组中TEAE显著存在（RR:1.26；95%CI:1.00-1.59；p=0.05）。结论尽管我们的分析表明IL-23抑制剂对治疗银屑病关节炎有效，但需要进一步研究长期结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Immunology Communications

自引率

0.00%

发文量